Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2013 - 2026)

Sarepta Therapeutics has reported Non-Current Deffered Revenue for 10 years, with the latest figure at $136.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 58.04% year-over-year to $136.4 million; the trailing twelve-month figure through Mar 2026 stood at $136.4 million (down 58.04% YoY), and the FY2025 full-year result was $83.9 million, down 74.18% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $136.4 million, up from $83.9 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $552.2 million in Q1 2022, with the low at $83.9 million in Q4 2025.
• Average Non-Current Deffered Revenue over 5 years is $387.5 million, with a median of $437.0 million recorded in 2023.
• Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2025, while the deepest fall reached 74.18% in 2025.
• Tracing SRPT's Non-Current Deffered Revenue over 5 years: stood at $485.0 million in 2022, then retreated by 9.9% to $437.0 million in 2023, then declined by 25.63% to $325.0 million in 2024, then slumped by 74.18% to $83.9 million in 2025, then jumped by 62.5% to $136.4 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $136.4 million (Q1 2026), $83.9 million (Q4 2025), and $325.0 million (Q1 2025), per Business Quant data.

Peer Comparison